



FEDERAL ELECTION COMMISSION  
WASHINGTON, D.C. 20463

RQ-2

January 4, 2022

TODD SPALDING, TREASURER  
ALEXION PHARMACEUTICALS INC. PAC  
1455 PENNSYLVANIA AVE NW SUITE 510  
WASHINGTON, DC 20004

**Response Due Date**  
**02/08/2022**

IDENTIFICATION NUMBER: C00471169

REFERENCE: DECEMBER MONTHLY REPORT (11/01/2021 - 11/30/2021)

Dear Treasurer:

This letter is prompted by the Commission's preliminary review of the report referenced above. This notice requests information essential to full public disclosure of your federal election campaign finances. **Failure to adequately respond by the response date noted above could result in an audit or enforcement action.** Additional information is needed for the following **1** item(s):

- Schedule B of your report (see attached) discloses one or more contributions which appear to exceed the limits set forth in the Act. Please be advised that 52 U.S.C. §30116(a) prohibits a multicandidate committee **and its affiliates** from making a contribution to a candidate for federal office in excess of \$5,000 per election.

If any apparently excessive contribution in question was incompletely or incorrectly disclosed, you should amend your original report with clarifying information.

If any contribution you made exceeds the limits, you must request a refund of the excessive amount or provide a written authorization for a redesignation of the contribution pursuant to 11 CFR §110.2(b) within 60 days of the treasurer's receipt.

If the foregoing conditions for redesignations were not met within 60 days of the treasurer's receipt, your committee must obtain a refund of the excessive amount.

Please inform the Commission of your corrective action promptly by providing the date and method of your remedy (refund or redesignation request) for each contribution. The committee should retain for its records copies of the refund and/or redesignation request(s) sent to the recipient committee(s). In addition,

ALEXION PHARMACEUTICALS INC. PAC

Page 2 of 2

any refunds should be disclosed on Schedule A supporting Line 16 of the report covering the period during which they are received. Any redesignations should be disclosed as memo entries on Schedule B supporting Line 23 of the report covering the period during which the redesignation is made. (11 CFR §110.1(b))

Although the Commission may take further legal action regarding the excessive contribution(s), your prompt action in obtaining a refund and/or redesignating the contribution(s) will be taken into consideration. (11 CFR §103.3(b)(1) and (3))

**Please note, you will not receive an additional notice from the Commission on this matter.** Adequate responses must be received by the Commission on or before the due date noted above to be taken into consideration in determining whether audit action will be initiated. Failure to comply with the provisions of the Act may also result in an enforcement action against the committee. Any response submitted by your committee will be placed on the public record and will be considered by the Commission prior to taking enforcement action. **Requests for extensions of time in which to respond will not be considered.**

Electronic filers must file amendments (to include statements, designations and reports) in an electronic format and must submit an amended report in its entirety, rather than just those portions of the report that are being amended. For information about the report review process or specific filing information for your committee type, please visit [www.fec.gov/help-candidates-and-committees](http://www.fec.gov/help-candidates-and-committees). For more information about Requests for Additional Information (RAI), why you received a letter, and how to respond, please visit [www.fec.gov/help-candidates-and-committees/request-additional-information](http://www.fec.gov/help-candidates-and-committees/request-additional-information). Should you have any questions regarding this matter or wish to verify the adequacy of your response, please contact me on our toll-free number (800) 424-9530 (at the prompt press 5 to reach the Reports Analysis Division) or my local number(202) 694-1185.

Sincerely,



Michael Beckman

Sr. Campaign Finance & Reviewing Analyst

**Apparent Excessive Contributions**  
**Alexion Pharmaceuticals Inc. PAC (C00471169)**

**Apparent Excessive Contributions to a Committee/Candidate Committee**

<b>Recipient Name</b>	<b>Date</b>	<b>Amount</b>	<b>Election</b>	<b>Report</b>	<b>Contributing Affiliate</b>
Lisa Blunt Rochester For Congress	11/22/21	\$2,500.00	P2022	2021 December Monthly	C00471169
Lisa Blunt Rochester For Congress	11/30/21	\$5,000.00	P2022	2021 December Monthly	C00279455
Curtis For Congress	5/5/21	\$1,500.00	P2022	2021 June Monthly	C00471169
Curtis For Congress	7/29/21	\$2,500.00	P2022	2021 August Monthly	C00279455
Curtis For Congress	11/2/21	\$1,000.00	P2022	2021 December Monthly	C00279455
Curtis For Congress	11/22/21	\$1,000.00	P2022	2021 December Monthly	C00471169